Citations (19)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Sylwia Milewska, Katarzyna Niemirowicz-Laskowska, Gabriela Siemiaszko, Piotr Nowicki, Agnieszka Z Wilczewska & Halina Car. (2021) Current Trends and Challenges in Pharmacoeconomic Aspects of Nanocarriers as Drug Delivery Systems for Cancer Treatment. International Journal of Nanomedicine 16, pages 6593-6644.
Read now
Read now
Johanna M van Dongen, Mohamed El Alili, Anita N Varga, Alejandra E Guevara Morel, Angela Jornada Ben, Mojdeh Khorrami, Maurits W van Tulder & Judith E Bosmans. (2020) What do national pharmacoeconomic guidelines recommend regarding the statistical analysis of trial-based economic evaluations?. Expert Review of Pharmacoeconomics & Outcomes Research 20:1, pages 27-37.
Read now
Read now
Ye Zhao, Hai-ming Feng, Ji Qu, Xiu Luo, Wen-juan Ma & Jin-hui Tian. (2018) A systematic review of pharmacoeconomic guidelines. Journal of Medical Economics 21:1, pages 85-96.
Read now
Read now
Articles from other publishers (16)
Maria Bucek Psenkova, Lucia Hlavinkova, Martin Visnansky, Dominik Grega & Martina Ondrusova. (2024) The Checklist for Standard Methodological Requirements and Reporting of Economic Evaluation of Medicines in Slovakia. Value in Health Regional Issues 39, pages 14-19.
Crossref
Crossref
Gaylene Pron, Matthew Hwang, Mehran Nasralla, Roger Smith, Angela Cheung & Kieran Murphy. (2023) Cost-effectiveness and willing-to-pay thresholds for vertebral augmentation of osteoporotic vertebral fractures, what are they based on: a systematic review. BMJ Open 13:7, pages e062832.
Crossref
Crossref
Claudia Fischer, Susanne Mayer, Nataša Perić & Judit Simon. (2022) Harmonization issues in unit costing of service use for multi-country, multi-sectoral health economic evaluations: a scoping review. Health Economics Review 12:1.
Crossref
Crossref
Gaylene Pron, Matthew Hwang, Roger Smith, Angela Cheung & Kieran Murphy. (2022) Cost-effectiveness studies of vertebral augmentation for osteoporotic vertebral fractures: a systematic review. The Spine Journal 22:8, pages 1356-1371.
Crossref
Crossref
Sanjib Saha, Ulf Gerdtham, Mats Bläckberg, Petter Kollberg & Fredrik Liedberg. (2022) Cost Effectiveness of the Use of Prophylactic Mesh To Prevent Parastomal Hernia After Urinary Diversion with an Ileal Conduit. European Urology Open Science 40, pages 9-15.
Crossref
Crossref
Thomas Hammerschmidt. 2022. Gesundheitswissenschaften. Gesundheitswissenschaften
779
790
.
Deepshikha Sharma, Arun Kumar Aggarwal, Laura E. Downey & Shankar Prinja. (2021) National Healthcare Economic Evaluation Guidelines: A Cross-Country Comparison. PharmacoEconomics - Open 5:3, pages 349-364.
Crossref
Crossref
José Antonio Sacristán, José-María Abellán-Perpiñán, Tatiana Dilla, Javier Soto & Juan Oliva. (2020) Some reflections on the use of inappropriate comparators in CEA. Cost Effectiveness and Resource Allocation 18:1.
Crossref
Crossref
Tzu-Chun Chou, Shao-Chin Chiang & Yu Ko. (2020) Health state utilities for metastatic breast cancer in Taiwan. The Breast 51, pages 57-64.
Crossref
Crossref
M. Hiligsmann, J.-Y. Reginster, A.N.A. Tosteson, S.V. Bukata, K.G. Saag, D.T. Gold, P. Halbout, F. Jiwa, E.M. Lewiecki, D. Pinto, J.D. Adachi, N. Al-Daghri, O. Bruyère, M. Chandran, C. Cooper, N.C. Harvey, T.A. Einhorn, J.A. Kanis, D.L. Kendler, O.D. Messina, R. Rizzoli, L. Si & S. Silverman. (2018) Recommendations for the conduct of economic evaluations in osteoporosis: outcomes of an experts’ consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the US branch of the International Osteoporosis Foundation. Osteoporosis International 30:1, pages 45-57.
Crossref
Crossref
Thomas Hammerschmidt. 2019. Gesundheitswissenschaften. Gesundheitswissenschaften
669
680
.
Thomas Hammerschmidt. 2018. Gesundheitswissenschaften. Gesundheitswissenschaften
1
12
.
Tim A. Kanters, Clazien A. M. Bouwmans, Naomi van der Linden, Siok Swan Tan & Leona Hakkaart-van Roijen. (2017) Update of the Dutch manual for costing studies in health care. PLOS ONE 12:11, pages e0187477.
Crossref
Crossref
Lan Gao, Hao Hu, Fei-Li Zhao & Shu-Chuen Li. (2016) Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples. PLOS ONE 11:1, pages e0147169.
Crossref
Crossref
Emelie Heintz, Andreas Gerber-Grote, Salah Ghabri, Francoise F. Hamers, Valentina Prevolnik Rupel, Renata Slabe-Erker & Thomas Davidson. (2015) Is There a European View on Health Economic Evaluations? Results from a Synopsis of Methodological Guidelines Used in the EUnetHTA Partner Countries. PharmacoEconomics 34:1, pages 59-76.
Crossref
Crossref
Clazien Bouwmans, Marieke Krol, Hans Severens, Marc Koopmanschap, Werner Brouwer & Leona Hakkaart-van Roijen. (2015) The iMTA Productivity Cost Questionnaire. Value in Health 18:6, pages 753-758.
Crossref
Crossref